

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

PANGENOMIC HEALTH INC.
102 - 3800 Wesbrook Mall
Vancouver, BC
V6S2L9

Item 2. Date of Material Change

July 18, 2022

Item 3. News Release

The news release was issued on July 18, 2022 and was disseminated by Cision PR Newswire.

Item 4. Summary of Material Change

The Class A Common Shares (the "Common Shares") of PanGenomic Health Inc. (the "Company") have been approved for listing (the "Listing") and will commence trading on the Canadian Securities Exchange ("CSE") effective July 18, 2022, under the trading symbol "NARA".

The escrow release conditions for the Company's non-brokered financing of 7,365,999 subscription receipts (each a "Subscription Receipt") at a price of \$0.15 per Subscription Receipt for aggregate gross proceeds of \$1,104,900 (the "Financing") have been satisfied. As a result, each Subscription Receipt was automatically exchanged for one unit (a "Unit") of the Company and the proceeds of the Financing were released to the Company from escrow.

Item 5. Full Description of Material Change

Pursuant to the bulletin published by the CSE on July 15, 2022 approving the Listing, the Common Shares will commence trading on the CSE effective July 18, 2022, under the trading symbol "NARA".

The escrow release conditions for the Financing have been satisfied. As a result, each Subscription Receipt has been exchanged for one Unit for no additional consideration and the proceeds of the Financing have been released to the Company. Each Unit consists of one Common Share and one Common Share purchase warrant (each a "Warrant"). Each Warrant entitles the holder to purchase one additional Common Share at a price of \$0.30 per share for a period ending 24 months from the date the escrow release conditions were satisfied, subject to acceleration.

The net proceeds of the Financing will be used for the development and releases of the Company's Nara App (Phases 2 and 3) and PlantGx Platform (Phase 2), marketing and investor relations expenses, expenses related to the Prospectus and the Listing, general and administrative expenses and general working capital purposes.

Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Tammy Gillis
CFO, Treasurer and Secretary
778.743.4642

Item 9. Date of Report

July 18, 2022